{'fraction_non_alphanumeric': 0.01445966514459665, 'fraction_numerical': 0.0060882800608828, 'mean_word_length': 5.848958333333333, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ANTIDIABETIC ACTIVITY OF BENZYL TETRA ISOQUINOLINE ALKALOID BERBERINE IN STREPTOZOTOCIN-NICOTINAMIDE INDUCED TYPE 2 DIABETIC RATS

SUMMARY The antidiabetic potential of berberine was evaluated in a streptozotocin-nicotinamide induced type 2 diabetic rat model. On administration of graded doses of berberine to normal and experimental diabetic rats for 12 days, a significant (p<0.05) reduction was observed in fasting blood glucose levels. However, serum insulin levels failed to be stimulated on treatment with berberine. Significant changes were observed in serum lipid profiles, thiobarbituric acid reactive substance levels, glycosylated hemoglobin and liver glycogen levels in berberine treated diabetic rats as compared with diabetic control and normal animals. The effect of berberine was also studied for its carbohydrate metabolism and antioxidant status in streptozotocin-nicotinamide induced type 2 diabetic rats. Oral administration of berberine caused a significant increase in both enzymatic and nonenzymatic antioxidants. Studies of the effect of berberine on glycolytic enzymes showed a significant increase in their levels whilst a significant decrease was observed in the levels of the gluconeogenic enzymes in treated diabetic rats. Serum creatinine and urea levels also declined significantly.